Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus missed its primary endpoint, failing to achieve statistical significance on CLASI-A percent change from baseline at Week 12. Although positive numerical trends were seen and deeper IgG reductions correlated with better responses, the company said the results fell below its internal bar and it will stop development in CLE.
Key figures
- Drug Name
- IMVT-1402 (imeroprubart)
- Phase Of Trial
- proof-of-concept
- Result
- did not achieve statistical significance
- Primary endpoint
- percent change from baseline in CLASI-A score at Week 12
- Patients enrolled
- 57
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.